journal
MENU ▼
Read by QxMD icon Read
search

Prostate

journal
https://www.readbyqxmd.com/read/28503903/the-23rd-annual-prostate-cancer-foundation-scientific-retreat-report
#1
REVIEW
Andrea K Miyahira, Howard R Soule
INTRODUCTION: The 23rd Annual Prostate Cancer Foundation (PCF) Scientific Retreat was convened October 27-29, 2016, in Carlsbad, CA. METHODS: This event focuses on the latest advances in basic, translational, and clinical prostate cancer research with the greatest promise for advancing our understanding of prostate cancer biology and improving patient outcomes and quality of life. RESULTS: Themes highlighted at this year's meeting included: i) targeting DNA repair deficiency in prostate cancer; ii) optimizing the use of Radium-223 and bone-targeting agents; iii) advances in cancer immunotherapeutic approaches; iv) targeting developmental pathways in prostate cancer; v) advances in circulating tumor DNA technology and applications; vi) precision survivorship; and vii) novel treatments and treatment strategies in prostate cancer...
May 14, 2017: Prostate
https://www.readbyqxmd.com/read/28497488/the-common-parasite-toxoplasma-gondii-induces-prostatic-inflammation-and-microglandular-hyperplasia-in-a-mouse-model
#2
Darrelle L Colinot, Tamila Garbuz, Maarten C Bosland, Liang Wang, Susan E Rice, William J Sullivan, Gustavo Arrizabalaga, Travis J Jerde
BACKGROUND: Inflammation is the most prevalent and widespread histological finding in the human prostate, and associates with the development and progression of benign prostatic hyperplasia and prostate cancer. Several factors have been hypothesized to cause inflammation, yet the role each may play in the etiology of prostatic inflammation remains unclear. This study examined the possibility that the common protozoan parasite Toxoplasma gondii induces prostatic inflammation and reactive hyperplasia in a mouse model...
May 12, 2017: Prostate
https://www.readbyqxmd.com/read/28370267/external-validation-of-a-nomogram-for-identification-of-pathologically-favorable-disease-in-intermediate-risk-prostate-cancer-patients
#3
Jean-Baptiste Beauval, Bastien Cabarrou, Giorgio Gandaglia, Pierre-Marie Patard, Adil Ouzzane, Alexandre de la Taille, Michel Soulié, Alberto Briganti, Guillaume Ploussard, François Rozet, Mathieu Roumiguié
OBJECTIVE: To establish an external validation of the new nomogram from Gandaglia et al which provides estimates of the probability of pathological favorable disease in pre-operatively defined intermediate-risk PCa. PATIENTS AND METHODS: Overall, 2928 intermediate-risk PCa patients according to the D'Amico classification undergoing RP and bilateral lymph node dissection in seven academic centres between 2000 and 2011. Pathologically favorable PCa was defined as low-grade organ-confined disease...
April 2, 2017: Prostate
https://www.readbyqxmd.com/read/28295408/circulating-tumor-cells-as-a-marker-for-progression-free-survival-in-metastatic-castration-na%C3%A3-ve-prostate-cancer
#4
Andreas Josefsson, Anna Linder, Despina Flondell Site, Giacomo Canesin, Anna Stiehm, Aseem Anand, Anders Bjartell, Jan-Erik Damber, Karin Welén
BACKGROUND: Analysis of circulating tumor cells (CTC) is a promising prognostic marker in castration-resistant prostate cancer (CRPC). The aim of this study was to investigate CTC detection and phenotyping as prognostic biomarkers for response to primary androgen deprivation therapy (ADT) of metastatic prostate cancer (PC). METHODS: PC patients presenting with a prostate specific antigen (PSA) >80 ng/ml and/or metastatic disease, intended for ADT were enrolled in the study...
March 10, 2017: Prostate
https://www.readbyqxmd.com/read/28261834/the-association-of-diabetes-and-obesity-with-prostate-cancer-progression-hcap-nc
#5
Saira Khan, Jianwen Cai, Matthew E Nielsen, Melissa A Troester, James L Mohler, Elizabeth T H Fontham, Laura H Hendrix, Laura Farnan, Andrew F Olshan, Jeannette T Bensen
BACKGROUND: The role of race in modifying the association among diabetes, obesity, and prostate cancer (CaP) progression is not well studied. We evaluated diabetes and obesity in association with time to CaP progression in White Americans (Whites) and Black Americans (Blacks). METHODS: Our study sample consisted of 363 White and 284 Black research participants from the Health Care Access and CaP Treatment in North Carolina (HCaP-NC) cohort. The association between self-reported diabetes or obesity and CaP progression (mean follow-up time approximately 5 years) was assessed using Cox proportional hazards modeling, with adjustment for potential confounders...
March 6, 2017: Prostate
https://www.readbyqxmd.com/read/28247425/estimating-heritability-of-prostate-cancer-specific-survival-using-population-based-registers
#6
Robert Szulkin, Mark S Clements, Patrik K E Magnusson, Fredrik E Wiklund, Ralf Kuja-Halkola
BACKGROUND: There is a strong genetic component in prostate cancer development with an estimated heritability of 58%. In addition, recent epidemiological assessments show a familial component in prostate cancer-specific survival, which could be due to either common genetics or environment. In this study we sought to estimate the heritability of prostate cancer-specific survival by studying brothers and father-son pairs in Sweden. METHODS: We used linkage records from three Swedish national registers: the Multi-Generation Register, the Cancer Register, and the Cause of Death Register...
March 1, 2017: Prostate
https://www.readbyqxmd.com/read/28247415/novel-monoclonal-antibodies-recognizing-human-prostate-specific-membrane-antigen-psma-as-research-and-theranostic-tools
#7
Zora Nováková, Catherine A Foss, Benjamin T Copeland, Volker Morath, Petra Baranová, Barbora Havlínová, Arne Skerra, Martin G Pomper, Cyril Barinka
BACKGROUND: Prostate-specific membrane antigen (PSMA) is a validated target for the imaging and therapy of prostate cancer. Here, we report the detailed characterization of four novel murine monoclonal antibodies (mAbs) recognizing human PSMA as well as PSMA orthologs from different species. METHODS: Performance of purified mAbs was assayed using a comprehensive panel of in vitro experimental setups including Western blotting, immunofluorescence, immunohistochemistry, ELISA, flow cytometry, and surface-plasmon resonance...
March 1, 2017: Prostate
https://www.readbyqxmd.com/read/28240424/intraductal-carcinoma-of-the-prostate-on-diagnostic-needle-biopsy-predicts-prostate-cancer-mortality-a-population-based-study
#8
Thorstein Saeter, Ljiljana Vlatkovic, Gudmund Waaler, Einar Servoll, Jahn M Nesland, Karol Axcrona, Ulrika Axcrona
BACKGROUND: Intraductal carcinoma of the prostate (IDC-P) is a distinct histopathologic feature associated with high-grade, advanced prostate cancer. Although studies have shown that IDC-P is a predictor of progression following surgical or radiation treatment for prostate cancer, there are sparse data regarding IDC-P on diagnostic needle biopsy as a prognosticator of prostate cancer mortality. MATERIALS AND METHODS: This was a population-based study of all prostate cancer patients diagnosed using needle biopsy and without evidence of systemic disease between 1991 and 1999 within a defined geographic region of Norway...
February 27, 2017: Prostate
https://www.readbyqxmd.com/read/28240376/iap-antagonists-enhance-apoptotic-response-to-enzalutamide-in-castration-resistant-prostate-cancer-cells-via-autocrine-tnf-%C3%AE-signaling
#9
Amanda B Pilling, Ok Hwang, Alain Boudreault, Alain Laurent, Clara Hwang
BACKGROUND: Castration-resistant prostate cancer (CRPC) remains incurable and identifying effective treatments continues to present a clinical challenge. Although treatment with enzalutamide, a second generation androgen receptor (AR) antagonist, prolongs survival in prostate cancer patients, responses can be limited by intrinsic resistance or acquired resistance. A potential mechanism of resistance to androgen axis inhibition is evasion of apoptosis. Inhibitor of apoptosis proteins (IAPs) are found to be overexpressed in prostate cancer and function to block apoptosis and promote survival signaling...
February 27, 2017: Prostate
https://www.readbyqxmd.com/read/28485104/microrna-181a-promotes-docetaxel-resistance-in-prostate-cancer-cells
#10
Cameron M Armstrong, Chengfei Liu, Wei Lou, Alan P Lombard, Christopher P Evans, Allen C Gao
BACKGROUND: Docetaxel is one of the primary drugs used for treating castration resistant prostate cancer (CRPC). Unfortunately, over time patients invariably develop resistance to docetaxel therapy and their disease will continue to progress. The mechanisms by which resistance develops are still incompletely understood. This study seeks to determine the involvement of miRNAs, specifically miR-181a, in docetaxel resistance in CRPC. METHODS: Real-time PCR was used to measure miR-181a expression in parental and docetaxel resistant C4-2B and DU145 cells (TaxR and DU145-DTXR)...
June 2017: Prostate
https://www.readbyqxmd.com/read/28480542/the-effect-of-non-steroidal-anti-inflammatory-drugs-on-risk-of-benign-prostatic-hyperplasia
#11
Lotta H Nygård, Kirsi Talala, Kimmo Taari, Teuvo L J Tammela, Anssi Auvinen, Teemu J Murtola
BACKGROUND: Inflammation may play a role in pathogenesis of benign prostatic hyperplasia (BPH). However, the role of non-steroidal anti-inflammatory drugs (NSAIDs) as BPH risk factor is unclear. The objective of this study was to examine risk of BPH by NSAID use in a population-based cohort. METHODS: A total of 74 754 Finnish men without previous BPH at baseline in 1996-1999 were linked to national medication reimbursement database for information on physician-prescribed NSAID purchases during 1995-2009...
June 2017: Prostate
https://www.readbyqxmd.com/read/28480526/profile-of-cell-proliferation-and-apoptosis-activated-by-the-intrinsic-and-extrinsic-pathways-in-the-prostate-of-aging-rats
#12
Amanda C R Gonzaga, Gabriel H Campolina-Silva, Hipácia Werneck-Gomes, Júnia D Moura-Cordeiro, Letícia C Santos, Germán A B Mahecha, Mônica Morais-Santos, Cleida A Oliveira
BACKGROUND: Estrogens acting through the receptors ERα and ERβ participate in prostate normal growth and cancer. ERβ is highly expressed in the prostate epithelium, playing pro-apoptotic, anti-proliferative, and pro-differentiation roles. Apoptosis is activated by the intrinsic pathway after castration and by the extrinsic pathway after ERβ agonist treatment. This differential activation of apoptotic pathways is important since a major problem in the treatment of prostate cancer is the recurrence of tumors after androgen withdrawal...
June 2017: Prostate
https://www.readbyqxmd.com/read/28449236/discovery-of-lhrh-and-development-of-lhrh-analogs-for-prostate-cancer-treatment
#13
REVIEW
Andrew V Schally, Norman L Block, Ferenc G Rick
The discovery, isolation, elucidation of structure, synthesis, and initial testing of the neuropeptide hypothalamic luteinizing hormone-releasing hormone (LHRH), which regulates reproduction, is briefly described. The design, synthesis, and experimental and clinical testing of agonistic analogs of LHRH is extensively reviewed focusing on the development of new methods for the treatment of prostate cancer. Subsequent development of antagonistic analogs of LHRH is then faithfully recounted with special emphasis on therapy of prostate cancer and BPH...
June 2017: Prostate
https://www.readbyqxmd.com/read/28429423/erratum
#14
Alice S Whittemore
No abstract text is available yet for this article.
June 2017: Prostate
https://www.readbyqxmd.com/read/28429372/long-term-clinical-impact-of-psa-surge-in-castration-resistant-prostate-cancer-patients-treated-with-abiraterone
#15
Vincenza Conteduca, Orazio Caffo, Cristian Lolli, Michele Aieta, Emanuela Scarpi, Emanuela Bianchi, Francesca Maines, Giuseppe Schepisi, Samanta Salvi, Francesco Massari, Francesco Carrozza, Antonello Veccia, Vincenzo E Chiuri, Enrico Campadelli, Gaetano Facchini, Ugo De Giorgi
BACKGROUND: Early changes in PSA have been evaluated in association to treatment outcome. The aim of this study was to assess PSA surge phenomenon in castration-resistant prostate cancer (CRPC) patients treated with abiraterone and to correlate those variations with long-term treatment outcome. PATIENTS AND METHODS: We retrospectively evaluated 330 CRPC patients in 11 Italian hospitals, monitoring PSA levels at baseline and every 4 weeks. Other clinical, biochemical and molecular parameters were determined at baseline...
June 2017: Prostate
https://www.readbyqxmd.com/read/28422308/androgen-receptor-regulated-mirna-193a-3p-targets-ajuba-to-promote-prostate-cancer-cell-migration
#16
Li Jia, Bin Gui, Dali Zheng, Keith F Decker, Ilker Tinay, Mingyue Tan, Xiaowei Wang, Adam S Kibel
Background Dysregulation of microRNA (miRNA) expression is implicated in cancer development and progression by modulating oncogenes or tumor suppressors at the post-transcriptional level. Methods To investigate the role of miRNAs in prostate cancer (PCa) progression, we performed small RNA-sequencing (RNA-seq) analysis in androgen-dependent LNCaP cells and LNCaP-derived castration-resistant prostate cancer (CRPC) C4-2B cells. For functional validation, we specifically investigated miR-193a-3p, which is highly upregulated in C4-2B cells and modulated by the androgen receptor (AR)...
June 2017: Prostate
https://www.readbyqxmd.com/read/28422303/smoking-increased-the-risk-of-prostate-cancer-with-grade-group%C3%A2-%C3%A2-%C3%A2-4-and-intraductal-carcinoma-in-a-prospective-biopsy-cohort
#17
Bo Tang, Cheng-Tao Han, Hua-Lei Gan, Gui-Ming Zhang, Cui-Zhu Zhang, Wei-Yi Yang, Ying Shen, Yao Zhu, Ding-Wei Ye
OBJECTIVE: To investigate the association between smoking and different prostate cancer (PCa) pathological subtypes incidence in Chinese men. PATIENTS AND METHODS: We prospectively included 1795 patients who underwent prostate biopsies in one tertiary center between March 2013 and April 2016. Clinical data and biopsy outcomes were collected. Logistic regression was used to evaluate the association between cigarette smoking and PCa incidence. RESULTS: A total of 737 men, 480 men and 58 men were diagnosed with PCa, high-grade PCa (HGPCa, grade group ≥ 4 as accepted by the 2014 ISUP) and intraductal carcinoma of the prostate (IDC-P), respectively...
June 2017: Prostate
https://www.readbyqxmd.com/read/28419548/detection-of-prostate-cancer-specific-transcripts-in-extracellular-vesicles-isolated-from-post-dre-urine
#18
Kathryn L Pellegrini, Dattatraya Patil, Kristen J S Douglas, Grace Lee, Kathryn Wehrmeyer, Mersiha Torlak, Jeremy Clark, Colin S Cooper, Carlos S Moreno, Martin G Sanda
BACKGROUND: The measurement of gene expression in post-digital rectal examination (DRE) urine specimens provides a non-invasive method to determine a patient's risk of prostate cancer. Many currently available assays use whole urine or cell pellets for the analysis of prostate cancer-associated genes, although the use of extracellular vesicles (EVs) has also recently been of interest. We investigated the expression of prostate-, kidney-, and bladder-specific transcripts and known prostate cancer biomarkers in urine EVs...
June 2017: Prostate
https://www.readbyqxmd.com/read/28419541/when-should-active-surveillance-for-prostate-cancer-stop-if-no-progression-is-detected
#19
Tiago M de Carvalho, Eveline A M Heijnsdijk, Harry J de Koning
BACKGROUND: A significant proportion of screen-detected men with prostate cancer may be overdiagnosed. Active Surveillance (AS) has emerged as a way to mitigate this problem, by delaying treatment of men, who are at low-risk until this becomes necessary. However, it is not known after how much time or biopsy rounds should patients stop AS and transition to conservative management (CM), if no progression is detected. METHODS: We used a microsimulation model with natural history of prostate cancer based on ERSPC and SEER data...
June 2017: Prostate
https://www.readbyqxmd.com/read/28401578/dual-action-of-high-estradiol-doses-on-mnu-induced-prostate-neoplasms-in-a-rodent-model-with-high-serum-testosterone-protective-effect-and-emergence-of-unstable-epithelial-microenvironment
#20
Bianca F Gonçalves, Silvana G P de Campos, Rejane M Góes, Wellerson R Scarano, Sebastião R Taboga, Patricia S L Vilamaior
BACKGROUND: Estrogens are critical players in prostate growth and disease. Estrogen therapy has been the standard treatment for advanced prostate cancer for several decades; however, it has currently been replaced by alternative anti-androgenic therapies. Additionally, studies of its action on prostate biology, resulting from an association between carcinogens and estrogen, at different stages of life are scarce or inconclusive about its protective and beneficial role on induced-carcinogenesis...
June 2017: Prostate
journal
journal
20232
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"